Oral small molecule GLP-1 receptor agonist
Orforglipron 12 mg oral once daily
ORFO_PO_12MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 36 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.79 (-2.14 to -1.34) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.27 (-1.75 to -0.74) | 0.62 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.40 (-2.23 to -0.18) | 0.58 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.12 (-8.62 to -1.04) | 0.76 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.44 (-7.90 to -2.68) | 0.50 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -4.07 (-8.28 to 1.21) | 0.51 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 11.30 (1.07 to 38.49) | 0.57 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 6.39 (1.22 to 18.35) | 0.79 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.01 to 20.33) | 0.68 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -4.18 (-6.69 to -1.71) | 0.74 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.27 (-7.15 to 2.51) | 0.43 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Semaglutide 14 mg oral once daily (original tablet) | MD -1.39 (-8.30 to 5.60) | 0.66 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -6.28 (-12.60 to 0.94) | 0.74 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.10 (1.43 to 13.70) | 0.76 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.08 (-0.75 to 0.92) | 0.52 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.08 (0.77 to 1.49) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.00 (3.74 to 6.80) | 0.24 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.04 (4.14 to 8.79) | 0.24 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.08 (1.61 to 2.69) | 0.37 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.51 (2.55 to 4.90) | 0.19 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.65 (0.01 to 53.48) | 0.56 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.88 (0.05 to 14.24) | 0.47 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.24 (0.00 to 6.13) | 0.66 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.88 (-15.02 to 7.20) | 0.56 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -8.14 (-14.54 to 0.90) | 0.24 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.70 (-13.11 to 3.01) | 0.35 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.07 (0.52 to 2.13) | 0.53 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.18 (3.02 to 5.86) | 0.41 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.21 (3.63 to 10.11) | 0.35 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.55 (1.56 to 4.14) | 0.36 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.55 (1.95 to 6.27) | 0.26 |
Trials
- ACHIEVE-3A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)2023 · 1,698 randomized · 52 weeks
- ATTAIN-2A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)2023 · 1,613 randomized · 72 weeks
- ACHIEVE-5A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor2023 · 546 randomized · 40 weeks
- ATTAIN-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)2023 · 3,127 randomized · 72 weeks
- ACHIEVE-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone2023 · 559 randomized · 40 weeks
- NCT05086445A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus2021 · 62 randomized · 12 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT05051579A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 272 randomized · 36 weeks